Equities
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRK:NYQ since
announced
Transaction
value
Revolution Medicines IncPrior rumour discounted08 Jan 202608 Jan 2026Prior rumour discounted11.80%--
MoonLake ImmunotherapeuticsRumoured02 Jun 202502 Jun 2025Rumoured58.00%--
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Caixa DTVM SAas of 30 Sep 2025218.16k0.00%
Safra Asset CTVM SA (Investment Management)as of 30 Sep 202558.10k0.00%
XP Allocation Asset Management Ltda.as of 30 Sep 20252.55k0.00%
E2M Investimentos Ltda.as of 30 Sep 20251.35k0.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.